证券代码：002742 证券简称：ST 三圣 公告编号：2023-77 号 重庆三圣实业股份有限公司 关于控股股东被司法拍卖的股份完成过户 暨被动减持的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆三圣实业股份有限公司（以下简称"公司"）于 2023 年 8 月 10 日通过 中国证券登记结算有限责任公司深圳分公司(以下简称"中登结算公司")系统 查询获悉，公司控股股东潘先文先生被司法拍卖的 3,931,311 股公司股份已完成 过户登记手续，现将有关情况公告如下： 一、司法拍卖的情况 山东省烟台市中级人民法院于 2023 年 7 月 15 日 10 时起至 2023 年 7 月 16 日 10 时止在阿里拍卖平台上（网址：https://sf-item.taobao.com）对潘先文 先生持有的 3,931,311 股公司股份进行司法拍卖，根据拍卖平台公示的《网络竞 价成交确认书》，竞买人烟台安林果业有限公司以最高价竞得 3,931,311 股，具 体内容详见公司于 2023 年 7 月 18 日在巨潮资讯网上披露的《关于控股股东及其 一致行动人 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 20%[20]. - The company's operating revenue for 2022 was ¥2,077,023,564.35, a decrease of 16.56% compared to ¥2,489,145,222.21 in 2021[25]. - The net profit attributable to shareholders was -¥317,882,092.06, showing an improvement of 4.67% from -¥333,437,976.48 in the previous year[25]. - The cash flow from operating activities was ¥49,115,363.42, down 64.88% from ¥139,837,805.19 in 2021[25]. - The basic earnings per share were -¥0.7358, a 4.66% improvement from -¥0.7718 in 2021[25]. - The company's total revenue for 2022 was ¥2,077,023,564.35, representing a year-on-year decrease of 16.56%[46]. - The construction materials segment generated revenue of ¥1,139,303,933.06, down 28.04% year-on-year, primarily due to instability in the construction industry[46]. - The pharmaceutical segment achieved revenue of ¥915,556,556.10, an increase of 5.58% year-on-year, supported by large-scale customer collaborations and the launch of the second phase of Baikang Pharmaceutical[47]. Market Strategy and Outlook - The company has outlined a future outlook with a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[20]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[20]. - A strategic acquisition of a local competitor is in progress, expected to enhance the company's production capacity by 40%[20]. - The company is actively investing in pharmaceutical and new building material projects in line with the "Belt and Road" national strategy, enhancing its market expansion efforts[41]. - The company plans to divest overseas businesses through public listing to minimize the impact of international operations on overall performance[85]. Operational Efficiency and Cost Management - The company has implemented new operational strategies aimed at reducing costs by 15% over the next year[20]. - The company is focusing on optimizing production and adjusting product prices to stabilize operations amid rising raw material costs and market competition[46]. - The company aims to strengthen its organizational structure and performance evaluation systems to enhance talent development and management efficiency[49]. - The company is committed to promoting its corporate culture to support sustainable growth and align with its strategic objectives[49]. Internal Control and Governance - The company has acknowledged internal control deficiencies, particularly regarding the influence of the actual controller on operations, and is taking steps to address these issues[5]. - The audit report from Tianjian Accounting Firm highlighted significant uncertainties regarding the company's ongoing operations, which investors should consider[5]. - The company has identified significant internal control deficiencies related to the misuse of funds by major shareholders and has taken corrective measures[119]. - The company has implemented corrective measures to enhance internal control systems, including training management on compliance and risk awareness[127]. - The company has established a responsibility framework for rectification involving the chairman, senior executives, and heads of relevant departments[132]. Environmental Compliance and Sustainability - The company strictly adheres to multiple environmental protection laws and standards, including the Water Pollution Prevention Law and Air Pollution Prevention Law[141]. - The company’s emissions for particulate matter are below 30 mg/m3, complying with the cement industry air pollutant discharge standards[142]. - The company reported a total emission of 36.25 tons of particulate matter and 348.3 tons of nitrogen oxides annually[142]. - The company has implemented strategies to reduce ammonia emissions to below 20 mg/Nm3, aligning with industry standards[143]. - The company is focused on continuous improvement in its environmental management systems to enhance operational efficiency and reduce emissions[143]. Leadership and Management Changes - The company experienced a significant leadership change with the appointment of new executives, including the election of Yan Huan as Chairman on September 29, 2022[95]. - The company reported a total of 12 leadership changes, including the departure of the previous Chairman and General Manager, Xiang Liping, due to the expiration of his term[95]. - The new management team includes Zhang Zhiqiang as General Manager and Yin Yunling as Chief Financial Officer, both appointed on September 29, 2022[95]. - The leadership transition is expected to drive future growth and innovation within the company, aligning with its long-term strategic goals[97]. Shareholder Relations and Transparency - The company ensures shareholder rights by providing both in-person and online voting options for shareholders[152]. - The company maintains investor relations through regular disclosures and a dedicated investor hotline[152]. - The company is committed to transparency by designating specific media for information disclosure[152]. - The company has reported a total of 476,124 shares held by the chairman, with a decrease of 286,900 shares due to personal financial needs, resulting in a final holding of 189,224 shares[93]. Financial Obligations and Liabilities - The company is facing significant financial pressure due to rising raw material prices and the need to repay interest-bearing debts, leading to tight cash flow[85]. - The company has incurred a total repayment obligation of CNY 80.331 million due to guarantees provided for loans taken by its overseas subsidiary[125]. - The company has a total guarantee amount of 9,000, with actual amounts incurred being 5,000, reflecting a significant commitment[185]. - The company has a structured guarantee system with a mix of joint and individual responsibilities, enhancing financial stability[185]. Compliance and Regulatory Issues - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[194]. - The company has faced administrative regulatory measures from the China Securities Regulatory Commission regarding non-operating asset occupation and delayed information disclosure[170]. - The company has not reported any environmental accidents during the reporting period[151].

Financial Performance - The company's revenue for Q1 2023 was ¥497,422,619.12, representing a 9.63% increase compared to ¥453,744,979.80 in the same period last year[4] - The net profit attributable to shareholders was -¥34,412,609.33, a significant decrease of 756.42% from ¥5,242,468.17 in the previous year[4] - The net loss for Q1 2023 was CNY 24,355,311.87, compared to a net profit of CNY 11,543,202.81 in Q1 2022, indicating a significant decline in profitability[15] - The total operating revenue for Q1 2023 was CNY 497,422,619.12, an increase of 9.5% compared to CNY 453,744,979.80 in Q1 2022[14] - The total operating costs for Q1 2023 were CNY 512,667,501.08, up from CNY 457,827,141.40 in the same period last year, reflecting a rise of 12%[14] - The total comprehensive income attributable to the parent company was -37,059,088.03 CNY, compared to -3,585,025.85 CNY in the previous period, indicating a significant decline[16] Cash Flow - The net cash flow from operating activities improved to ¥36,369,854.68, a 264.94% increase from -¥22,050,335.26 in the same period last year[4] - Cash inflow from operating activities totaled 338,506,529.46 CNY, down 16.9% from 407,791,041.72 CNY in the previous period[17] - Cash outflow from operating activities was 302,136,674.78 CNY, a decrease of 29.7% compared to 429,841,376.98 CNY in the previous period[18] - The company reported a net cash flow from investing activities of -7,859,846.29 CNY, an improvement from -17,120,899.80 CNY in the previous period[18] - Cash inflow from financing activities was 51,500,000.00 CNY, down 74.1% from 199,100,000.00 CNY in the previous period[18] - The cash and cash equivalents at the end of the period increased to 111,239,758.76 CNY from 37,040,785.00 CNY in the previous period[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,904,145,227.78, down 3.38% from ¥4,040,800,589.29 at the end of the previous year[4] - The total liabilities decreased to CNY 2,960,482,016.93 from CNY 3,049,147,892.85, showing a decline of about 2.9%[12] - The total equity attributable to shareholders decreased to CNY 765,412,346.74 from CNY 802,312,531.40, a decline of approximately 4.6%[12] - The accounts receivable decreased by 46.53% to ¥29,668,921.04 from ¥55,491,615.19 in the previous year[6] Earnings and Expenses - The weighted average return on equity was -4.40%, a decrease of 4.87% compared to 0.47% in the previous year[4] - The company reported a basic and diluted earnings per share of -¥0.0797, a decline of 758.68% from ¥0.0121 in the same period last year[4] - Research and development expenses for Q1 2023 were CNY 3,575,571.99, a decrease from CNY 4,898,797.18 in Q1 2022, reflecting a reduction of approximately 26.9%[15] - The company reported a significant increase in financial expenses, totaling CNY 25,246,599.32, compared to CNY 33,963,433.27 in the previous year, indicating a decrease of about 25.7%[15] - The company recorded non-operating income and expenses totaling -¥2,730,912.47 after tax adjustments[5] Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,565[7] - The company experienced a foreign currency translation difference of -2,646,478.70 CNY, compared to -8,827,494.02 CNY in the previous period[16] - The cash and cash equivalents were not explicitly stated, but the total current assets amounted to CNY 1,668,578,088.65, down from CNY 1,762,179,285.85[12]

Group 1: Event Details - The event will take place on December 23, 2022, from 15:00 to 17:00 [1] - Investors can participate through the "Panorama Roadshow" platform [1] Group 2: Company Commitment - The company guarantees the authenticity, accuracy, and completeness of the disclosed information [1] - There are no false records, misleading statements, or significant omissions [1] Group 3: Interaction Focus - Senior management will address governance, operational status, and sustainable development during the online communication [1] - The format of the interaction will be "one-to-many" [1] Group 4: Investor Engagement - The company encourages active participation from investors [1]

编号：2015-001 号 证券代码：002742 证券简称：三圣特材 重庆三圣特种建材股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------|-------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | | □媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | 机构投资者： | | | 参与单位名称及 | | 1、国泰君安证券股份有限公司：鲍雁辛、黄涛 | | | 2 | 、工银瑞信基金管理有限公司：孔薇薇 | | 人员姓名 | 3 | 、深圳民森投资有限公司：张庭坚 | | | 个人投资者：郭可 | | | 时间 | 2015 年 4 月 13 | 日上午 11 点 | | 地点 | 公司证券事务部 | | | 上市公司接待人 员姓名 | 总经理张志强 ...

编号：2015-002 号 证券代码：002742 证券简称：三圣特材 重庆三圣特种建材股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------|----------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | | □媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | 1 | 、中银国际证券有限责任公司：王钦 | | | 2 | 、国联安基金管理有限公司：顾益辉 | | | 3 | 、广发证券股份有限公司：谢璐 | | 参与单位名称及 | 4 | 、国泰君安证券资产管理公司：祝捷 | | 人员姓名 | 5 | 、安诚财产保险股份有限公司：卢敬之 | | | 6 | 、国信证券经济研究所、重庆分公司：黄道立、周 | | | 忻、宋占宇、刘宏 | | | 时间 | 2015 年 11 月 | ...

Group 1: Mergers and Acquisitions - The company has completed the acquisition of LiaoYuan BaiKang Pharmaceutical and is currently restructuring and merging with ChunRui Medical [2][3] - The company emphasizes the stability of the original management team of the acquired entities, retaining key personnel while integrating new members to enhance management [3] - Both BaiKang Pharmaceutical and ChunRui Medical are 100% wholly acquired, chosen over a controlling stake due to their historical background and dispersed shareholding structure [4] Group 2: Strategic Focus and Development - The company's short-term focus is on effectively integrating the acquired companies to lay a solid foundation for diversification and development in the pharmaceutical sector [4] - The chairman, with a military background, prioritizes industrial development and aims to enhance the company's profitability and intrinsic value through practical operations [4][5] - The company is committed to building a research and development platform and integrating the pharmaceutical industry chain to create a manufacturing base for specialty intermediates and active pharmaceutical ingredients [3] Group 3: Financial and Regulatory Aspects - The company has received feedback from the China Securities Regulatory Commission regarding its restructuring and fundraising plans, and will respond accordingly [5] - Some executives have reduced their holdings due to personal financial needs and the accumulation of funds, with the reduction being a legal right of shareholders [6] - The company plans to allocate funds raised from the public offering based on the pricing mechanism and subscription quotes after obtaining regulatory approval [6]

编号：2017-001 号 证券代码：002742 证券简称：三圣股份 重庆三圣实业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | 1 | 、广发证券发展研究中心 谢璐 | | | 2 | 、银河基金研究部 王翊 | | 参与单位名称及 | 3 | 、招商证券研究发展中心 郑晓刚、李点典 | | 人员姓名 | 4 | 、东吴证券研究所 焦德智 | | | 5 | 、国海富兰克林基金研究分析部 赵宇烨 | | 时间 | 2017 年 5 月 22 | 日 | | 地点 | 公司 1212 会议室 | | | 上市公司接待人 | | 董事长潘先文、董事 ...

Group 1: Company Overview and Strategy - The company aims to strengthen and optimize its first industry in building materials and chemicals while significantly developing its second industry in pharmaceuticals [3] - Ethiopia is chosen for investment due to its political stability, strategic partnership with China, and a population of over 90 million, presenting substantial development potential [3] - The company plans to follow the national strategy of "going global" and enhance investments in building materials and pharmaceuticals in Ethiopia [4] Group 2: Financial Performance and Projections - The gross profit margin for the building materials project is approximately 40%, while the pharmaceutical project has not yet commenced production, but is expected to have a considerable gross profit margin [4] - The company expresses confidence in its 2018 operational outlook, despite recent increases in cement prices due to environmental pressures and capacity restrictions [5] Group 3: Investment and Development Plans - The company is focusing on building a complete pharmaceutical manufacturing chain, including intermediates, raw materials, and formulations, while integrating international strategies [5] - A professional pharmaceutical management team and research center have been established to enhance resource integration and internal management [5] Group 4: Stakeholder Engagement and Future Initiatives - The company is considering implementing an equity incentive plan to enhance team cohesion and is exploring various methods for this initiative [6] - The chairman of the company expresses strong confidence in the future development strategy, supporting sustainable and healthy growth [6]

证券代码：002742 证券简称：三圣股份 重庆三圣实业股份有限公司 投资者关系活动记录表 编号：2017-002 号 | --- | --- | --- | |----------------|-------------------------------------|------------------------------------------------------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | 其他（深交所联合重庆证监局在公司举办"践行中国梦•走 | | | 近上市公司"投资者开放日活动） | | | | 1 | 、通过西南证券、红塔证券、上海证券、华福证券、 湘财证券、南京证券、广发证券、德同资本等报名的近 40 | | | | | | 人员姓名 | | 2、证券时报、证券日报、全景财经、第一财经等 8 | | 参 ...